NRIX

Nurix Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001549595
$17.07 +0.18% $1.8B
Insider Selling Cluster (3 insiders)High Impact Filing (8/10)14 New Institutional Positions3 Institutional Exits
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders50 funds
Inst. Value$896.9M
Inst. Activity14 buys / 3 sells
Insider Activity0B / 13S
Insider Net $-$1.4M
SEC Reports8
Press Releases2
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001549595·Prev Close $17.04

Recent Activity

Jun 16, 2026 short_volume
Short Volume: NRIX — 73.4% short (0.5M / 0.7M)
Short: 526,807 | Exempt: 80 | TRF Vol: 717,741 | Short Ratio: 73.4% | Off-exchange volume (dark pool
Jun 11, 2026 SEC
Eight institutional investors accumulated $278.7M in NRIX shares during Q4 2025, primarily through mega-passive index fu
INST-CLUSTER — Impact 4/10
Jun 8, 2026 SEC
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commerciali
8-K — Impact 8/10
Jun 8, 2026 Press
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral
Impact 8/10
Jun 2, 2026 Insider
Ring Christine acquired via exercise 3,422 shares
Chief Legal Officer @ $1.86 ($6.4K)
Jun 2, 2026 Insider
Ring Christine sold 8,148 shares
Chief Legal Officer @ $16.60 ($135.3K)
May 15, 2026 Insider
GREGORY JULIA P was granted 31,250 shares
Director
May 5, 2026 SEC
Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-day window, with the C
CLUSTER — Impact 3/10

Price Targets

$31.00 +81.6% upside Strong Buy
Current $17.07 Low $23.00 Median $31.00 High $45.00 16 analysts
$23.00 $45.00

Analyst Ratings

Strong Buy96% buy · 23 analysts
8Strong Buy
14Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 15, 2026 Needham REITERATE Buy → Buy
Jun 10, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Jun 9, 2026 Truist Securities MAINTAIN Buy → Buy
Jun 9, 2026 BTIG MAINTAIN Buy → Buy
Jun 8, 2026 Jefferies MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.71 ▲ +1.0% $-0.86 — $-0.50 -36% YoY 14
Next Q $-0.24 ▲ +67.9% $-0.85 — $5.69 77% YoY 14
Current FY $-2.35 ▲ +20.2% $-3.28 — $3.70 23% YoY 13
Next FY $-2.68 ▲ +6.4% $-3.49 — $-1.65 -14% YoY 12

Latest Reports

NEUTRAL INST-CLUSTER 4/10
Eight institutional investors accumulated $278.7M in NRIX shares during Q4 2025, primarily through mega-passive index fu
Jun 11, 2026
BULLISH 8-K 8/10
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commerciali
Jun 8, 2026
BULLISH Press 8/10
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral
Jun 8, 2026

Top Institutional Holders

FundValueMove
NOMURA ASSET MANAGEMENT CO——
BlackRock, Inc.$138.3MADD
FMR LLC$85.9MADD
STATE STREET CORP$79.7MADD
MORGAN STANLEY$76.4MDOUBLED

Recent Insider Trades

DateInsiderTypeValue
Jun 2, 2026Ring ChristineM$6.4K
Jun 2, 2026Ring ChristineSELL$135.3K
May 15, 2026GREGORY JULIAA$0.00
May 15, 2026Baynes RoyA$0.00
May 15, 2026DANSEY ROGERA$0.00
50 institutional holders with $896.9M total value (57,859,437 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, FMR. Net buying activity: 14 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1NOMURA ASSET MANAGEMENT CO LTD—$0.000.0%—
2BlackRock, Inc.8,925,642$138.3M15.4%ADD +31.2%
3FMR LLC5,541,271$85.9M9.6%ADD +30.9%
4STATE STREET CORP5,141,195$79.7M8.9%ADD +44.4%
5MORGAN STANLEY4,931,999$76.4M8.5%DOUBLED +115.9%
6BAKER BROS. ADVISORS LP4,658,556$72.2M8.1%—
7VANGUARD CAPITAL MANAGEMENT LLC4,427,112$68.6M7.7%—
8Pictet Asset Management Holding SA2,726,138$42.3M4.7%ADD +75.1%
9Rubric Capital Management LP2,473,885$38.3M4.3%NEW
10DEUTSCHE BANK AG\2,295,024$35.6M4.0%NEW
11ARK Investment Management LLC1,721,135$26.7M3.0%—
12CITADEL ADVISORS LLC1,343,700$20.8M2.3%TRIM -64.4%
13GOLDMAN SACHS GROUP INC1,318,659$20.4M2.3%—
14Sumitomo Mitsui Trust Group, Inc.1,181,146$18.3M2.0%—
15VANGUARD PORTFOLIO MANAGEMENT LLC1,102,266$17.1M1.9%—
16Woodline Partners LP925,444$14.3M1.6%DOUBLED +1109.0%
17CHARLES SCHWAB INVESTMENT MANAGEMENT INC924,039$14.3M1.6%ADD +42.4%
18Capital World Investors893,327$13.8M1.5%NEW
19Nuveen, LLC812,601$12.6M1.4%DOUBLED +415.9%
20BANK OF AMERICA CORP /DE/802,153$12.4M1.4%ADD +53.1%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
FMR LLCADD4,234,1585,541,271+30.9%$85.9M2026-Q1
STATE STREET CORPADD3,559,5015,141,195+44.4%$79.7M2026-Q1
Capital World InvestorsNEW—893,327—$13.8M2026-Q1
DIMENSIONAL FUND ADVISORS LPADD430,986780,696+81.1%$12.1M2026-Q1
Point72 Asset Management, L.P.NEAR_EXIT3,211,680449,106-86.0%$7.0M2026-Q1
Trexquant Investment LPDOUBLED77,359209,694+171.1%$3.3M2026-Q1
Invesco Ltd.TRIM343,830203,609-40.8%$3.2M2026-Q1
Rafferty Asset Management, LLCADD90,515149,523+65.2%$2.3M2026-Q1
SEI INVESTMENTS CODOUBLED35,97682,108+128.2%$1.3M2026-Q1
Russell Investments Group, Ltd.ADD63,48281,841+28.9%$1.3M2026-Q1
AMERIPRISE FINANCIAL INCTRIM124,74961,825-50.4%$958.3K2026-Q1
VICTORY CAPITAL MANAGEMENT INCDOUBLED20,52061,774+201.0%$957.5K2026-Q1
Brevan Howard Capital Management LPADD20,68026,501+28.1%$410.8K2026-Q1
Rockefeller Capital Management L.P.DOUBLED1,0685,318+397.9%$82.4K2026-Q1
NISA INVESTMENT ADVISORS, LLCDOUBLED7262,556+252.1%$39.6K2026-Q1
CWM, LLCDOUBLED174841+383.3%$13.0K2026-Q1
Allworth Financial LPADD94145+54.3%$2.2K2026-Q1
BlackRock, Inc.ADD6,762,5868,875,194+31.2%$168.4M2025-Q4
VANGUARD GROUP INCADD4,488,7765,949,512+32.5%$112.9M2025-Q4
MORGAN STANLEYDOUBLED2,260,7464,881,069+115.9%$92.6M2025-Q4
FMR LLCTRIM8,887,5374,234,158-52.4%$80.3M2025-Q4
Pictet Asset Management Holding SAADD1,980,5403,467,600+75.1%$65.8M2025-Q4
DEUTSCHE BANK AG\NEW—2,486,792—$47.2M2025-Q4
Rubric Capital Management LPNEW—2,473,885—$46.9M2025-Q4
Woodline Partners LPDOUBLED76,544925,444+1109.0%$17.6M2025-Q4
12 unique insiders with 36 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 2, 2026Ring ChristineChief Legal OfficerEXERCISE3,422$1.86$6.4K
Jun 2, 2026Ring ChristineChief Legal OfficerSELL8,148$16.60$135.3K
May 15, 2026GREGORY JULIA PDirectorAWARD31,250——
May 15, 2026Baynes Roy D.DirectorAWARD31,250——
May 15, 2026DANSEY ROGER DDirectorAWARD31,250——
May 15, 2026Kapur AnilDirectorAWARD31,250——
May 15, 2026Lacey David L.DirectorAWARD31,250——
May 15, 2026Reinsdorf Judith ADirectorAWARD31,250——
May 15, 2026Saltzman Edward CDirectorAWARD31,250——
May 15, 2026Silva Paul MDirectorAWARD31,250——
May 5, 2026van Houte HansChief Financial OfficerSELL13,473$16.58$223.3K
May 4, 2026Ring ChristineChief Legal OfficerSELL8,148$16.96$138.2K
May 1, 2026Ring ChristineChief Legal OfficerSELL5,394$16.76$90.4K
Apr 30, 2026Hansen GwennChief Scientific OfficerEXERCISE2,000——
Apr 30, 2026Hansen GwennChief Scientific OfficerSELL3,214$16.65$53.5K
Apr 30, 2026Ring ChristineChief Legal OfficerEXERCISE2,000——
Apr 30, 2026Ring ChristineChief Legal OfficerSELL3,214$16.65$53.5K
Apr 30, 2026van Houte HansChief Financial OfficerEXERCISE2,000——
Apr 30, 2026van Houte HansChief Financial OfficerSELL2,388$16.65$39.7K
Apr 2, 2026Ring ChristineChief Legal OfficerSELL8,148$15.24$124.1K
Mar 2, 2026Ring ChristineChief Legal OfficerSELL8,148$15.44$125.8K
Feb 10, 2026van Houte HansChief Financial OfficerAWARD42,875——
Feb 10, 2026van Houte HansChief Financial OfficerAWARD93,750——
Feb 10, 2026Ring ChristineChief Legal OfficerAWARD42,875——
Feb 10, 2026Ring ChristineChief Legal OfficerAWARD93,750——
Feb 10, 2026Hansen GwennChief Scientific OfficerAWARD42,875——
Feb 10, 2026Hansen GwennChief Scientific OfficerAWARD93,750——
Feb 10, 2026SANDS ARTHUR TPresident, CEOAWARD562,500——
Feb 9, 2026Ring ChristineChief Legal OfficerSELL14,261$16.66$237.6K
Feb 3, 2026Hansen GwennChief Scientific OfficerEXERCISE31,333$0.8400$26.3K
Jan 30, 2026van Houte HansChief Financial OfficerSELL3,588$16.58$59.5K
Jan 30, 2026van Houte HansChief Financial OfficerEXERCISE2,887——
Jan 30, 2026Ring ChristineChief Legal OfficerSELL4,333$16.58$71.9K
Jan 30, 2026Ring ChristineChief Legal OfficerEXERCISE1,925——
Jan 30, 2026Hansen GwennChief Scientific OfficerSELL4,797$16.58$79.5K
Jan 30, 2026Hansen GwennChief Scientific OfficerEXERCISE3,207——
8 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 5 neutral. Avg impact: 4.3/10.
NEUTRAL INST-CLUSTER 4/10
Eight institutional investors accumulated $278.7M in NRIX shares during Q4 2025, primarily through m
Jun 11, 2026
BULLISH 8-K 8/10
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develo
Jun 8, 2026
NEUTRAL CLUSTER 3/10
Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-da
May 5, 2026
NEUTRAL CLUSTER 2/10
Three NRIX insiders (CFO, CLO, CSO) sold a combined $231K in open-market sales, a trivial 0.014% of
May 4, 2026
NEUTRAL CLUSTER 2/10
Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of ~$184K in open-market shares ove
May 1, 2026
NEUTRAL CLUSTER 2/10
Two C-suite insiders at Nurix Therapeutics sold a combined $107K in open-market shares on April 30,
Apr 30, 2026
BEARISH PRESS-RELEASE 7/10
Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, an
Apr 21, 2026
BEARISH 8-K 6/10
Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million, down from $18.5
Apr 8, 2026
BULLISH 8/10
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize be
Jun 8, 2026
MIXED 6/10
Nurix Therapeutics presented new preclinical data at AACR 2026 across its oncology pipeline, includi
Apr 22, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 23 analysts: 8 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$31.00 mean target +81.6% upside Strong Buy (1.44)
$23.00 Low $45.00 High
MetricValue
Current Price$17.07
Target Low$23.00
Target Mean$31.00
Target Median$31.00
Target High$45.00
# Analysts16
RecommendationStrong Buy (1.44)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-05-31
 $-0.71 $-0.86 $-0.50 -36.1% +1.0% 10↑ 0↓ $0.0B -63.3% 14
Next Q
2026-08-31
 $-0.24 $-0.85 $5.69 77.0% +67.9% 10↑ 1↓ $0.1B 688.1% 14
Current FY
2026-11-30
 $-2.35 $-3.28 $3.70 22.9% +20.2% 9↑ 5↓ $0.1B 70.9% 13
Next FY
2027-11-30
 $-2.68 $-3.49 $-1.65 -13.9% +6.4% 9↑ 2↓ $0.1B -42.7% 12

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.708
7d ago$-0.715+0.007
30d ago$-0.715+0.007
60d ago$-0.727+0.019
90d ago$-0.792+0.084
10 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 15, 2026 Needham REITERATE Buy Buy
Jun 10, 2026 HC Wainwright & Co. REITERATE Buy Buy
Jun 9, 2026 Truist Securities MAINTAIN Buy Buy
Jun 9, 2026 BTIG MAINTAIN Buy Buy
Jun 8, 2026 Jefferies MAINTAIN Buy Buy
Jun 8, 2026 Wells Fargo MAINTAIN Overweight Overweight
Jun 8, 2026 Needham MAINTAIN Buy Buy
May 18, 2026 BTIG REITERATE Buy Buy
Apr 27, 2026 HC Wainwright & Co. REITERATE Buy Buy
Apr 23, 2026 Needham REITERATE Buy Buy
Apr 10, 2026 HC Wainwright & Co. REITERATE Buy Buy
Apr 9, 2026 Wells Fargo MAINTAIN Overweight Overweight
Apr 8, 2026 Needham REITERATE Buy Buy
Mar 24, 2026 HC Wainwright & Co. REITERATE Buy Buy
Jan 29, 2026 Piper Sandler MAINTAIN Overweight Overweight
Jan 29, 2026 RBC Capital MAINTAIN Outperform Outperform
Jan 29, 2026 Stifel MAINTAIN Buy Buy
Jan 29, 2026 Wells Fargo MAINTAIN Overweight Overweight
Jan 29, 2026 BTIG REITERATE Buy Buy
Jan 29, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Jan 29, 2026 Needham REITERATE Buy Buy
Jan 8, 2026 Morgan Stanley UPGRADE Equal-Weight Overweight

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202681410096%
May 1, 202681410096%
Apr 1, 202681410096%
Mar 1, 202681410096%
Feb 1, 202681410096%
Jan 1, 202681320091%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 16, 2026
short_volume
Short Volume: NRIX — 73.4% short (0.5M / 0.7M)
Short: 526,807 | Exempt: 80 | TRF Vol: 717,741 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)
Jun 15, 2026
short_volume
Short Volume: NRIX — 64.0% short (0.5M / 0.8M)
Short: 508,707 | Exempt: 400 | TRF Vol: 794,379 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Jun 12, 2026
short_volume
Short Volume: NRIX — 69.8% short (0.7M / 1.0M)
Short: 723,965 | Exempt: 31 | TRF Vol: 1,036,543 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: NRIX — 75.9% short (0.9M / 1.1M)
Short: 872,376 | Exempt: 0 | TRF Vol: 1,149,788 | Short Ratio: 75.9% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: NRIX — 59.6% short (1.9M / 3.2M)
Short: 1,890,356 | Exempt: 996 | TRF Vol: 3,169,816 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
contract
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
<p align="center"><em>Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted th
Jun 8, 2026
short_volume
Short Volume: NRIX — 59.2% short (4.5M / 7.5M)
Short: 4,460,349 | Exempt: 69,893 | TRF Vol: 7,534,436 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: NRIX — 56.8% short (0.3M / 0.6M)
Short: 324,375 | Exempt: 11 | TRF Vol: 570,898 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: NRIX — 78.1% short (1.0M / 1.2M)
Short: 952,609 | Exempt: 108 | TRF Vol: 1,219,284 | Short Ratio: 78.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Nurix Therapeutics to Participate in Upcoming Investor Conferences
<p>BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on
Apr 22, 2026
fda
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
<p align="center">Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs</p>
Apr 15, 2026
short_interest
FTD: NRIX — 36,456 shares ($0.6M) failed to deliver
Settlement: 20260415, Price: $16.30, FTD Value: $594,232.8, NURIX THERAPEUTICS INC
Apr 8, 2026
earnings
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
<p align="center"><em>Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic ly
Apr 6, 2026
earnings_calendar
NRIX Q1 2026 Earnings Scheduled — 2026-04-06
Mar 25, 2026
short_volume
Short Volume: NRIX — 56.2% short (0.6M / 1.1M)
Short: 618,291 | Exempt: 0 | TRF Vol: 1,100,157 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)